基础医学与临床 ›› 2016, Vol. 36 ›› Issue (5): 706-710.
• 短篇综述 • 上一篇 下一篇
白仲添,王海平,严俊,刘小军,周文策,李汛
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
基金资助:
Received:
Revised:
Online:
Published:
Contact:
摘要: 以嵌合型抗原受体(CAR)为基础的细胞治疗近年成为肿瘤生物治疗领域最亮丽的明星。尤其是靶向CD19分子的CAR-T细胞在B淋巴细胞恶性肿瘤的临床治疗中取得了良好的疗效。本文通过总结国内外CAR-T细胞的临床试验数据,对其临床疗效和潜在的不良反应进行统计分析,并就CAR-T细胞的发生、临床应用及存在的问题进行阐述。
关键词: 嵌合抗原受体, T细胞, 肿瘤, 临床试验
Abstract: Currently, chimeric antigen receptor, CAR-related cellular immunotherapy is venerated as the gorgeous star in tumor biotherapy. The CAR-T cell such as which targeted CD19 has obtained the good curative effect in conquering B lymphocyte malignancies. The latest CAT-T related references were collected and summarized to mainly analyse the data of clinical trial, clinical effects and potential adverse reaction treated with CAR-T.
Key words: Chimeric antigen receptor(CAR), T lymphocyte, tumor, clinical trial
白仲添 王海平 严俊 刘小军 周文策 李汛. CAR-T细胞在肿瘤临床试验中的研究进展[J]. 基础医学与临床, 2016, 36(5): 706-710.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2016/V36/I5/706